Research and Reports in Urology (Jun 2024)

Concomitant Prostate Needle Biopsy and Laser Vaporization of the Prostate Could Be a Risk of Postoperative Hemoglobin Decline, a Retrospective Study

  • Ezaki T,
  • Hongo H,
  • Takamatsu K,
  • Tanaka N,
  • Oya M

Journal volume & issue
Vol. Volume 16
pp. 123 – 129

Abstract

Read online

Taisuke Ezaki,1 Hiroshi Hongo,1 Kimiharu Takamatsu,1 Nobuyuki Tanaka,2 Mototsugu Oya2 1Department of Urology, Nerima General Hospital, Tokyo, Japan; 2Department of Urology, Keio University School of Medicine, Tokyo, JapanCorrespondence: Taisuke Ezaki, Department of Urology, Nerima General Hospital, 1-24-1 Asahigaoka, Nerima-Ku, Tokyo, 176-8530, Japan, Tel +81-3-5988-2200, Fax +81-3-5988-2250, Email [email protected]: Contact laser vaporization of the prostate (CVP) for benign prostatic hyperplasia is a widely accepted and safe procedure for elderly patients because of its lower bleeding risks. However, CVP lacks a postoperative pathological examination for prostate cancer. Concomitant prostate biopsy and CVP may complement this disadvantage; however, the risk of bleeding associated with this procedure remains unclear. This study aimed to evaluate the safety of a concomitant prostate biopsy and CVP.Patients and Methods: This retrospective study included 106 men who had undergone CVP in Nerima General Hospital. Prostate biopsies and CVP were performed simultaneously on 16 patients. We defined the “hemorrhage group” by a > 5% decrease in hemoglobin the day after surgery. Preoperative and operative indices were evaluated based on the association with the hemorrhage group.Results: Participants in the concomitant biopsy group were older (p = 0.001), had larger prostates (p = 0.014), a lower rate of prostate biopsy history (p = 0.046), longer postoperative urinary catheter duration (p = 0.024), and a higher rate of decline in hemoglobin levels the day after surgery (p = 0.023). Patients in the hemorrhage group (n = 20, 18.9%) showed a significantly higher rate of concomitant biopsy and CVP (p = 0.006). Multivariate analysis showed that concomitant prostate biopsy (p = 0.009, odds ratio = 4.61) was the sole statistically significant predictive factor for hemorrhage.Conclusion: Concomitant prostate biopsy and CVP of the prostate may increase the risk of bleeding.Keywords: benign prostatic hyperplasia, contact laser vaporization of the prostate, diode laser, prostate biopsy, vaporization

Keywords